In-Silico Drug Discovery Market Worth $ 40.3 Bn by 2031 - Exclusive Report by InsightAce Analytic

In-Silico Drug Discovery Market Worth $ 40.3 Bn by 2031 - Exclusive Report by InsightAce Analytic

In-Silico Drug Discovery Market Worth $ 40.3 Bn by 2031 - Exclusive Report by InsightAce Analytic

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global In-Silico Drug Discovery Market Size, Share & Trends Analysis By Products (Software, Software-as-a-Service (SaaS), Consultancy-as-a-Service), By Workflow (Discovery, Pre-Clinical Tests, Clinical Trials), By Technology(Artificial Intelligence, Graphics Processing Unit (GPU)), By Software Type (Molecular Modelling And De Novo Drug Design Software, Pharmacophore Modelling Software), By End User (Contract Research Organizations, Pharmaceutical And Biopharmaceutical Companies, Academic And Research Institutes)- Market Outlook And Industry Analysis 2031".

The Global In-Silico Drug Discovery Market is valued at US$ 10.9 Bn in 2023, and it is expected to reach US$ 40.3 Bn by 2031, with a CAGR of 18.05 % during the forecast period of 2024-2031.


Get A Free Report Brochure: https://insightaceanalytic.com/request-sample/2223


In-silico drug discovery has transformed pharmaceutical research by harnessing computational methods to identify and optimize potential drug candidates. Through techniques like virtual screening and molecular docking, researchers can swiftly sift through vast libraries of compounds to pinpoint those most likely to interact effectively with specific biological targets. This accelerates the early stages of drug discovery by focusing resources on promising candidates, thereby reducing time and costs traditionally associated with experimental screening. Moreover, in-silico methods such as QSAR modeling and molecular dynamics simulations refine lead compounds for enhanced potency, selectivity, and favorable drug-like properties. These predictive tools not only streamline the drug development process but also contribute to reducing reliance on animal testing by allowing researchers to assess potential efficacy and safety profiles early on.

The market for in-silico drug discovery offers a range of products and services tailored to meet the needs of pharmaceutical companies and research institutions. This includes sophisticated software platforms for molecular modeling and virtual screening, cloud-based solutions that provide scalable access to computational tools, and consultancy services staffed by experts in computational biology and drug discovery. Additionally, advancements in artificial intelligence and machine learning have further accelerated in-silico drug discovery by improving predictive modeling accuracy and enabling deeper insights from complex biological data. These technologies continue to drive innovation in drug development, offering new opportunities for discovering novel therapies and repurposing existing drugs for new indications, all while adhering to ethical considerations and regulatory standards.

List of Prominent Players in the In-Silico Drug Discovery Market:

·?????? Aragen Life Sciences

·?????? Curia Global

·?????? Certara

·?????? Charles River Associates

·?????? Chemical Computing Group

·?????? Collaborative Drug Discovery - CDD Vault

·?????? 达索系统

·?????? Evotec

·?????? Insilico Medicine

·?????? Ligand Pharmaceuticals

·?????? Numerated

·?????? 珀金埃尔默企业管理(上海)有限公司

·?????? Schr?dinger

·?????? Selvitas

·?????? Simulations Plus

·?????? Tracxn Technologies

·?????? WuXi AppTec

·?????? Others

Order this Premium Report: https://www.insightaceanalytic.com/buy-report/2223


Market Dynamics:

Drivers-

The escalating costs associated with traditional drug development methods, particularly in clinical trials, have driven pharmaceutical companies to adopt in-silico drug discovery techniques. In-silico approaches offer substantial cost savings by minimizing the number of compounds that require synthesis and experimental testing, thus streamlining the drug development process from virtual screening to molecular modeling.

Advances in computing power have further enhanced these capabilities, facilitating faster simulations and big data analyses. Moreover, the increasing adoption of cloud-based applications provides researchers with scalable computational resources, fostering collaboration, data sharing, and access to specialized tools. This convergence of cost-saving benefits and technological advancements underscores the pivotal role of in-silico drug discovery in accelerating timelines and improving efficiency in pharmaceutical research and development.

Challenges:

In-silico drug development faces regulatory challenges in validating computational models and integrating them into drug discovery practices. Limited availability of high-complexity testing centers and high costs are practical obstacles. Despite its potential to accelerate early-stage development, bridging the gap with experimental validation remains critical for ensuring drug safety and efficacy.

Regional Trends:

The demand for in-silico drug discovery in North America is propelled by the urgent need for treatments for rare diseases like Lou Gehrig's disease and cystic fibrosis, driven by a sizable patient population in the U.S. seeking innovative therapies. The region benefits from a flexible regulatory environment established by the U.S. FDA, which supports the adoption of computational methods in drug development through streamlined co-development processes. North America's advanced infrastructure and robust partnerships among service providers and manufacturers further bolster the market. Key players like Schrodinger, Dassault Systèmes, and Certara, headquartered in the region, contribute significantly to research and development efforts, enhancing the efficacy and accessibility of in-silico drug discovery solutions.


Recent Developments:

·?????? In March 2024, Selvita S.A. has announced a strategic initiative to expand into biologic drug discovery and development, focusing on therapeutic antibody discovery. This move includes adding a skilled team and fully equipped laboratories to their service portfolio.

·?????? In May 2024, Insilico Medicine initiated the first in-patient dose for ISM8207, a novel small molecule inhibitor targeting QPCTL, co-developed with Fosun Pharma for treating advanced malignant tumors.

·?????? In June 2024, Certara, Inc., a global leader in model-informed drug development, has launched an updated version of the Simcyp? Simulator for physiologically based pharmacokinetic (PBPK) modeling. This latest release introduces significant advancements designed to enhance decision-making capabilities for clients utilizing the simulator across all stages of drug development.

Get Specific Chapter/Information From The Report: https://www.insightaceanalytic.com/customisation/2223


Segmentation of In-Silico Drug Discovery Market-

By Products:

·?????? Software

·?????? Software-as-a-Service (SaaS)

·?????? Consultancy-as-a-Service

By Workflow:

·?????? Discovery

o?? Target Identification

§? Bioinformatics

§? Reverse Docking

§? Protein Structure Prediction

o?? Target Validation

o?? Lead Discovery

§? Library Design

§? Pharmacophore

o?? Pre-Clinical Tests

o?? Clinical Trials

By Technology:

·?????? Artificial Intelligence

·?????? Graphics Processing Unit (GPU)

·?????? Other Technologies

o?? In-Silico Fishing

o?? RNN for Drug Design

By Software Type-:

·?????? Molecular modelling and de novo drug design software

·?????? Pharmacophore Modelling software

By End User:

·?????? Contract Research Organizations

·?????? Pharmaceutical and Biopharmaceutical Companies

·?????? Academic and Research Institutes

·?????? Others

By Region-

North America-

·?????? The US

·?????? Canada

·?????? Mexico

Europe-

·?????? Germany

·?????? The UK

·?????? France

·?????? Italy

·?????? Spain

·?????? Rest of Europe

Asia-Pacific-

·?????? China

·?????? Japan

·?????? India

·?????? South Korea

·?????? Southeast Asia

·?????? Rest of Asia Pacific

Latin America-

·?????? Brazil

·?????? Argentina

·?????? Rest of Latin America

?Middle East & Africa-

·?????? GCC Countries

·?????? South Africa

·?????? Rest of Middle East and Africa

Details insights on this market: https://www.insightaceanalytic.com/report/in-silico-drug-discovery-market/2223


Why should buy this report:

?? To receive a comprehensive analysis of the prospects for global In-Silico Drug Discovery market

?? To receive industry overview and future trends of global In-Silico Drug Discovery market

?? To analyze the In-Silico Drug Discovery market drivers and challenges

?? To get information on the In-Silico Drug Discovery market size value (US$ Mn) forecast till 2031

?? Major Investments, Mergers & Acquisition in global In-Silico Drug Discovery industry

Other Related Reports Published by InsightAce Analytic:

AI-Enabled Drug Discovery and Clinical Trials Market

Clinical Trials Software Market

Artificial Intelligence in Epidemiology Market

System Integration Services Market

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact US:

InsightAce Analytic Pvt. Ltd.

Tel.: +1 718 593 4405

Email: [email protected]

Site Visit: www.insightaceanalytic.com

Follow Us on LinkedIn @ bit.ly/2tBXsgS

Follow Us On Facebook @ bit.ly/2H9jnDZ

要查看或添加评论,请登录

社区洞察

其他会员也浏览了